NASDAQ:OMCL

Omnicell (OMCL) Stock Forecast, Price & News

$48.50

-1.32 (-2.65%)

(As of 09/25/2023 ET)

Compare

Today's Range: $47.97
▼
$49.91
50-Day Range: $48.50
▼
$67.48
52-Week Range: $46.11
▼
$91.99

Volume: 557,512 shs
Average Volume: 493,197 shs
Market Capitalization: $2.19 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $68.75

Omnicell MarketRank™ Forecast

Analyst Rating: Hold
2.29 Rating Score
Upside/Downside: 41.8% Upside
$68.75 Price Target
Short Interest: Healthy
4.87% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.41
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 50.68%
From $0.73 to $1.10 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

275th out of 962 stocks

Electronic Computers Industry

4th out of 5 stocks

3.1

Analyst's Opinion

Consensus Rating
Omnicell has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $68.75, Omnicell has a forecasted upside of 41.8% from its current price of $48.50.
Amount of Analyst Coverage
Omnicell has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.87% of the outstanding shares of Omnicell have been sold short.
Short Interest Ratio / Days to Cover
Omnicell has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Omnicell has recently decreased by 0.90%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Omnicell does not currently pay a dividend.
Dividend Growth
Omnicell does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OMCL.

3.0

News and Social Media Coverage

News Sentiment
Omnicell has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Omnicell this week, compared to 3 articles on an average week.
Search Interest
1 people have searched for OMCL on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Omnicell to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Omnicell insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.61% of the stock of Omnicell is held by insiders.
Percentage Held by Institutions
99.18% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Omnicell are expected to grow by 50.68% in the coming year, from $0.73 to $1.10 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Omnicell is -93.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Omnicell is -93.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Omnicell has a PEG Ratio of 7.30. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Omnicell has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Omnicell (NASDAQ:OMCL) Stock

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Santa Clara, California.

OMCL Price History

30 days | 90 days | 365 days | Advanced Chart

OMCL Stock News Headlines

September 18, 2023 | finance.yahoo.com

An Intrinsic Calculation For Omnicell, Inc. (NASDAQ:OMCL) Suggests It's 32% Undervalued

September 16, 2023 | money.usnews.com

Omnicell, Inc.

September 25, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.

September 6, 2023 | finance.yahoo.com

Here's Why You Should Retain Omnicell (OMCL) Stock Now

September 5, 2023 | finance.yahoo.com

Unveiling Omnicell (OMCL)'s Value: Is It Really Priced Right? A Comprehensive Guide

August 30, 2023 | benzinga.com

Omnicell Inc. Unusual Options Activity: Slightly OTM Call Buying With Relative Size

August 25, 2023 | seekingalpha.com

Omnicell: Slowdown In Core Markets, Backlog Pressures Support Neutral Posture

August 23, 2023 | markets.businessinsider.com

Craig-Hallum Sticks to Their Buy Rating for Omnicell (OMCL)

September 25, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

August 23, 2023 | finance.yahoo.com

Omnicell to Present at the 2023 Wells Fargo Healthcare Conference

August 10, 2023 | seekingalpha.com

Omnicell, Inc. 2023 Q2 - Results - Earnings Call Presentation

August 2, 2023 | insidermonkey.com

Omnicell, Inc. (NASDAQ:OMCL) Q2 2023 Earnings Call Transcript

August 2, 2023 | gurufocus.com

Omnicell Inc: A Healthcare Stock with Good Outperformance Potential

August 2, 2023 | msn.com

Piper Sandler Downgrades Omnicell (OMCL)

August 2, 2023 | finance.yahoo.com

Omnicell (OMCL) Q2 Earnings and Revenues Top, '23 View Raised

August 2, 2023 | finance.yahoo.com

Q2 2023 Omnicell Inc Earnings Call

August 1, 2023 | finance.yahoo.com

Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates

August 1, 2023 | msn.com

Benchmark Reiterates Omnicell (OMCL) Buy Recommendation

August 1, 2023 | finance.yahoo.com

Omnicell Announces Second Quarter 2023 Results

July 21, 2023 | msn.com

Wells Fargo Downgrades Omnicell (OMCL)

July 20, 2023 | msn.com

Omnicell downgraded at Wells Fargo citing risks to YTD rally

July 20, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About Omnicell

July 18, 2023 | barrons.com

Omnicell Inc.

July 13, 2023 | benzinga.com

Keybanc Maintains Overweight on Omnicell, Raises Price Target to $80

July 13, 2023 | msn.com

Keybanc Maintains Omnicell (OMCL) Overweight Recommendation

July 12, 2023 | finance.yahoo.com

Omnicell to Release Second Quarter 2023 Financial Results on August 1, 2023

July 11, 2023 | finance.yahoo.com

Omnicell Appoints Bobby Ghoshal to Board of Directors

See More Headlines

Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Company Calendar

Last Earnings: 8/01/2023
Today: 9/25/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Electronic computers
Sub-Industry: Health Care Technology
Sector: Medical
Current Symbol: NASDAQ:OMCL
CUSIP: 68213N10
CIK: 926326
Web: www.omnicell.com
Phone: (877) 415-9990
Fax: 847-596-3402
Employees: 4,230
Year Founded: 1992

Price Target and Rating

Average Stock Price Forecast: $68.75
High Stock Price Forecast: $88.00
Low Stock Price Forecast: $54.00
Forecasted Upside/Downside: +41.8%
Consensus Rating: Hold
Rating Score (0-4): 2.29
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 66.44
P/E Growth: 7.3
Net Income: $5.65 million
Net Margins: -1.88%
Pretax Margin: -2.20%
Return on Equity: 4.47%
Return on Assets: 2.31%

Debt

Debt-to-Equity Ratio: 0.49
Current Ratio: 2.38
Quick Ratio: 2.03

Sales & Book Value

Annual Sales: $1.30 billion
Price / Sales: 1.69
Cash Flow: $4.08 per share
Price / Cash Flow: 11.88
Book Value: $25.52 per share
Price / Book: 1.90

Miscellaneous

Outstanding Shares: 45,210,000
Free Float: 44,032,000
Market Cap: $2.19 billion
Optionable: Optionable
Beta: 0.84

Social Links

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Randall A. Lipps (Age 66)
Founder, Exec. Chairman, Pres & CEO
Comp: $1.2M

Mr. Corey J. Manley
Exec. VP and Chief Legal & Admin. Officer

Mr. Nchacha Etta (Age 52)
Exec. VP & CFO

Ms. Minoo Mortazavi
Sr. VP of Global Operations

Mr. Joseph Brian Spears (Age 63)
Sr. VP, Chief Accounting Officer & Corp. Controller

Mr. Virad Gupta
Sr. VP & CTO

Mr. Giri Chodavarapu
Sr. VP & Chief Information Officer

Ms. Kathleen Nemeth
Sr. VP of Investor Relations

Mr. Maximo Rocha
Sr. VP & Chief People Officer

Mr. Jorge R. Taborga (Age 64)
Exec. VP of Engineering & Integration Management Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OMCL Stock - Frequently Asked Questions

Should I buy or sell Omnicell stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OMCL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMCL, but not buy additional shares or sell existing shares.
View OMCL analyst ratings or view top-rated stocks.
What is Omnicell's stock price forecast for 2023?: 7 Wall Street analysts have issued 12 month price objectives for Omnicell's stock. Their OMCL share price forecasts range from $54.00 to $88.00. On average, they anticipate the company's share price to reach $68.75 in the next twelve months. This suggests a possible upside of 41.8% from the stock's current price.
View analysts price targets for OMCL or view top-rated stocks among Wall Street analysts.
How have OMCL shares performed in 2023?: Omnicell's stock was trading at $50.42 at the start of the year. Since then, OMCL shares have decreased by 3.8% and is now trading at $48.50.
View the best growth stocks for 2023 here.
When is Omnicell's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our OMCL earnings forecast.
How were Omnicell's earnings last quarter?: Omnicell, Inc. (NASDAQ:OMCL) posted its earnings results on Tuesday, August, 1st. The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.30. The company earned $298.97 million during the quarter, compared to the consensus estimate of $285.25 million. Omnicell had a negative net margin of 1.88% and a positive trailing twelve-month return on equity of 4.47%.
What ETFs hold Omnicell's stock?: ETFs with the largest weight of Omnicell (NASDAQ:OMCL) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Global X Robotics & Artificial Intelligence ETF (BOTZ).iShares U.S. Medical Devices ETF (IHI).
What guidance has Omnicell issued on next quarter's earnings?: Omnicell updated its FY23 earnings guidance on Tuesday, August, 1st. The company provided earnings per share guidance of $1.75-$2.00 for the period, compared to the consensus estimate of $1.68. The company issued revenue guidance of $1.16-$1.20 billion, compared to the consensus revenue estimate of $1.18 billion.
What is Randall A. Lipps' approval rating as Omnicell's CEO?: 150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Omnicell own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).
What is Omnicell's stock symbol?: Omnicell trades on the NASDAQ under the ticker symbol "OMCL."
Who are Omnicell's major shareholders?: Omnicell's stock is owned by a variety of retail and institutional investors. Top institutional investors include Clearbridge Investments LLC (2.97%), Conestoga Capital Advisors LLC (2.48%), Champlain Investment Partners LLC (2.23%), Geneva Capital Management LLC (2.22%), Geode Capital Management LLC (2.06%) and Dimensional Fund Advisors LP (1.88%). Insiders that own company stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends.
How do I buy shares of Omnicell?: Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Omnicell's stock price today?: One share of OMCL stock can currently be purchased for approximately $48.50.
How much money does Omnicell make?: Omnicell (NASDAQ:OMCL) has a market capitalization of $2.19 billion and generates $1.30 billion in revenue each year. The company earns $5.65 million in net income (profit) each year or ($0.52) on an earnings per share basis.
How many employees does Omnicell have?: The company employs 4,230 workers across the globe.
Does Omnicell have any subsidiaries?: The following companies are subsidiares of Omnicell: 340B Investment LLC, 340B Link Business, 340B Link LLC, 340B Solutions LLC, Aesynt, Ateb Inc., FDS Amplicare, FDS Amplicare Company, FDS Inc., FDS Insurance Agency Inc., Flavma Inc., InPharmics, MTS Medication Technologies Inc., MTS Medication Technologies Inc., MTS Packaging Systems Inc., MarkeTouch Media LLC, MarkeTouch Media LLC, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd, Omnicell B.V., Omnicell GmbH, Omnicell India Private Limited, Omnicell International LLC, Omnicell Limited, Omnicell Pty Ltd, Omnicell S.r.l., Omnicell SAS, ReCept Cityview LLC, ReCept F&M LLC, ReCept Group Inc., ReCept Healthcare Services L.P., ReCept Holdings Inc., ReCept LLC, ReCept One LLC, ReCept Pharmacy, ReCept Pharmacy L.P., RxInnovation Inc., and ateb Inc..
Read More
How can I contact Omnicell?: Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is www.omnicell.com. The company can be reached via phone at (877) 415-9990, via email at ir@omnicell.com, or via fax at 847-596-3402.

This page (NASDAQ:OMCL) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial